Literature DB >> 2019191

Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers.

D A Thomas1, M A Myers, B Wichert, H Schreier, R J Gonzalez-Rothi.   

Abstract

Administering liposome-encapsulated drugs by aerosol is a feasible way of targeting drugs to the lungs. Prior to clinical application of aerosolized liposomes as drug carriers, their relative safety must be established. We evaluated the effects of inhaling nondrug-containing liposomes (15 and 150 mg of lipid per milliliter) for 1 h on pulmonary function and on oximetry in ten healthy nonsmoking volunteers. Spirometry was performed prior to and at intervals after inhalation, and subjects were monitored with pulse oximetry. Liposome inhalation was well tolerated, and no oxygen desaturation, decrements in pulmonary function, or side effects were noted. We conclude that inhalation of small particle aerosols of SPC liposomes produces no acute deleterious effects on pulmonary function in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2019191     DOI: 10.1378/chest.99.5.1268

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

2.  Liposomes for controlled delivery of drugs to the lung.

Authors:  K M Taylor; J M Newton
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

3.  Effects of cationic liposome-DNA complexes on pulmonary surfactant function in vitro and in vivo.

Authors:  P Boncuk; M Kaser; Y Yu; H W Taeusch
Journal:  Lipids       Date:  1997-03       Impact factor: 1.880

4.  Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability.

Authors:  Elke Kleemann; Thomas Schmehl; Tobias Gessler; Udo Bakowsky; Thomas Kissel; Werner Seeger
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

5.  Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.

Authors:  C E Cicogna; M H White; E M Bernard; T Ishimura; M Sun; W P Tong; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Carrier Effect in Development of Rifampin Loaded Proliposome for Pulmonary Delivery: A Quality by Design Study.

Authors:  Elahehnaz Parhizkar; Delaram Sadeghinia; Hamed Hamishehkar; Shadi Yaqoubi; Ali Nokhodchi; Shohreh Alipour
Journal:  Adv Pharm Bull       Date:  2021-05-18

Review 7.  Future developments in the pharmacotherapy of lung disease.

Authors:  A Van der Kuy
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

8.  Liposomal Antioxidants for Protection against Oxidant-Induced Damage.

Authors:  Zacharias E Suntres
Journal:  J Toxicol       Date:  2011-08-16

Review 9.  Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis.

Authors:  Melissa Skibba; Adam Drelich; Michael Poellmann; Seungpyo Hong; Allan R Brasier
Journal:  Front Pharmacol       Date:  2020-12-11       Impact factor: 5.810

Review 10.  Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.

Authors:  Malgorzata Smola; Thierry Vandamme; Adam Sokolowski
Journal:  Int J Nanomedicine       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.